We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 431

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused

By the numbers
  • King & Wood Mallesons
  • Australia
  • August 13 2014

The CMA has seen a decline in the overall number of merger decisions in the past year. It made 65 phase 1 merger decisions in 2013-14, down from 100

Below cost pricing?
  • King & Wood Mallesons
  • Australia
  • September 1 2014

According to reports in Friday's Australian FianancialRreview, (Hannah Low, page 32), the ACCC has sought to widen its claim against Pfizer. We

ACCC allegedly misled by Medicines Australia Code of Conduct
  • Russell Kennedy
  • Australia
  • August 25 2014

We previously reported that Medicines Australia submitted its 18th Edition of the Code of Conduct for approval by the ACCC. Subsequently, the Royal

Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its

Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd

ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend

Federal government’s “action plan” for Australia will the direct selling sector be affected?
  • Addisons
  • Australia
  • December 2 2014

In November 2014 the Australia federal government released its Industry Innovation and Competitiveness Agenda (the Agenda), a report1 outlining the

ACCC v Pfizer judgment summary and ramifications
  • Piper Alderman
  • Australia
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian

Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper